Venturini Massimo, Lanza Carolina, Marra Paolo, Colarieti Anna, Panzeri Marta, Augello Luigi, Gusmini Simone, Salvioni Marco, De Cobelli Francesco, Del Maschio Alessandro
Department of Radiology, Scientific Institute H S. Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
CVIR Endovasc. 2019 Feb 4;2(1):8. doi: 10.1186/s42155-019-0051-7.
Squid, as Onyx, is an ethylene-vinyl alcohol copolymer (EVOH)-based liquid embolic agent developed for neuroradiologic interventions with poor application in abdominal district. Our aim was to evaluate safety, complications, and efficacy of transcatheter embolization using the two available formulations Squid-18 and 12, in 30 patients affected by different abdominal diseases.
Transcatheter embolization with Squid, combined with other embolic agents, as poly vinyl alcohol (PVA) particles, coils and amplatzer plugs, or alone (type 2 endoleak), was performed in 30 patients, as follows: 10 portal vein embolizations (PVEs), 6 arteriovenous malformations (AVMs), 5 visceral artery aneurysms (VAAs), 4 type 2 endoleaks, 3 preoperative embolizations, 1 acute arterial bleeding, 1 female varicocele. Squid was always administered using dimethyl sulfoxide (DMSO) compatible microcatheters. Technical success, 30-day clinical success and complications were assessed. Technical success was 90%. 3 patients (2 AVMs, 1 VAA) required re-intervention successfully performed in all cases. Major complications, cases of microcatheter entrapment and DMSO-related poor pain control were not recorded. 30-day clinical success was 93.3%: in 2 patients submitted to PVE a sufficient future liver remnant (FLR) hypertrophy was not achieved.
Squid was successfully used with low complication rate in many abdominal diseases showing a valid embolic action either combined with other embolic agents or alone in type 2 endoleak. The availability of different formulations (Squid-18 and Squid-12) variable for viscosity makes Squid preferable to Onyx as EVOH-based liquid embolic agent, even though comparable studies in different abdominal districts with a larger cohort of patients will be necessary.
鱿鱼（Squid）作为一种基于乙烯-乙烯醇共聚物（EVOH）的液体栓塞剂，与玛瑙（Onyx）类似，是为神经放射介入治疗而开发的，但在腹部区域应用较少。我们的目的是评估使用两种可用配方鱿鱼-18和鱿鱼-12对30例患有不同腹部疾病的患者进行经导管栓塞术的安全性、并发症和疗效。
30例患者接受了鱿鱼经导管栓塞术，该栓塞术可与其他栓塞剂联合使用，如聚乙烯醇（PVA）颗粒、弹簧圈和Amplatzer封堵器，或单独用于2型内漏，具体如下：10例门静脉栓塞（PVE）、6例动静脉畸形（AVM）、5例内脏动脉瘤（VAA）、4例2型内漏、3例术前栓塞、1例急性动脉出血、1例女性精索静脉曲张。鱿鱼始终通过与二甲基亚砜（DMSO）兼容的微导管给药。评估了技术成功率、30天临床成功率和并发症。技术成功率为90%。3例患者（2例AVM、1例VAA）需要再次干预，所有病例均成功进行。未记录到主要并发症、微导管嵌顿病例和与DMSO相关的疼痛控制不佳情况。30天临床成功率为93.3%：2例接受PVE的患者未实现足够的未来肝残余（FLR）肥大。
鱿鱼在许多腹部疾病中成功使用，并发症发生率低，显示出有效的栓塞作用，可与其他栓塞剂联合使用，或单独用于2型内漏。不同配方（鱿鱼-18和鱿鱼-12）的粘度可变，这使得鱿鱼作为基于EVOH的液体栓塞剂比玛瑙更具优势，尽管需要在不同腹部区域对更多患者进行比较研究。
